Hospitalizations for Heart Failure With Preserved EF Common

This article originally appeared here.
Share this content:
Hospitalizations for Heart Failure With Preserved EF Common
Hospitalizations for Heart Failure With Preserved EF Common

MONDAY, Aug. 1, 2016 (HealthDay News) -- Heart failure with preserved ejection fraction (HFpEF) is common among patients hospitalized with acute heart failure, and patients with HFpEF are older, more often female, and frequently have comorbidities, according to a study published in the June issue of The American Journal of Medicine.

Parag Goyal, M.D., from the Weill Cornell Medical College in New York City, and colleagues examined 5,046,879 hospitalizations with a diagnosis of acute heart failure in 2003 to 2012 from the Nationwide Inpatient Sample. Hospitalizations were stratified by HFpEF and heart failure with reduced ejection fraction (HFrEF).

The researchers found that those with HFpEF were older, more often female, and more likely to have hypertension, atrial fibrillation, chronic lung disease, chronic renal failure, and anemia compared to those with HFrEF. HFpEF accounted for increasing proportions of men and patients aged 75 years and older over time. There was a 13 percent decrease in the in-hospital mortality rate, mainly due to improved survival in those aged 65 years or older. Pulmonary circulation disorders, liver disease, and chronic renal failure were independent predictors of in-hospital mortality, in multivariable regression analyses; inverse associations were seen for treatable diseases, including hypertension, coronary artery disease, and diabetes.

"Examination of a national representative sample of U.S. hospital discharges yielded identification of over two million hospitalizations with HFpEF, representing the largest cohort of HFpEF to date," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »